TY - JOUR
T1 - Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells
AU - Subramanian, Sandhya
AU - Yates, Melissa
AU - Vandenbark, Arthur A.
AU - Offner, Halina
PY - 2011/3
Y1 - 2011/3
N2 - Oestrogen (17β-oestradiol, E2) is a highly effective treatment for experimental autoimmune encephalomyelitis (EAE) that may potentiate Foxp3+ regulatory T (Treg) cells, which in turn limit the expansion of encephalitogenic T-cell specificities. To determine if Treg cells constitute the major non-redundant protective pathway for E2, we evaluated E2 protection of EAE after targeted deletion of Foxp3 expression in Foxp3-DTR mice. Unexpectedly, E2-treated Foxp3-deficient mice were completely protected against clinical and histological myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide-induced EAE before succumbing to diphtheria toxin-induced mortality. This finding indicated the presence of alternative E2-dependent EAE-protective pathways that could compensate for the lack of Treg cells. Further investigation revealed that E2 treatment inhibited proliferation and expression of CCL2 and CXCL2, but enhanced secretion of interleukin-10 (IL-10) and IL-13 by MOG-35-55-specific spleen cells. These changes occurred concomitantly with increased expression of several chemokines and receptors, including CXCL13 and CXCR5, and the negative co-activation molecules, PD-L1 and B7.2, by B cells and dendritic cells. Furthermore, E2 treatment resulted in higher percentages of spleen and lymph node T cells expressing IL-17, interferon-γ and tumour necrosis factor-α, but with lower expression of CCR6, suggesting sequestration of MOG-35-55 peptide-specific T cells in peripheral immune organs. Taken together, these data suggest that E2-induced mechanisms that provide protection against EAE in the absence of Foxp3+ Treg cells include induction of regulatory B cells and peripheral sequestration of encephalitogenic T cells.
AB - Oestrogen (17β-oestradiol, E2) is a highly effective treatment for experimental autoimmune encephalomyelitis (EAE) that may potentiate Foxp3+ regulatory T (Treg) cells, which in turn limit the expansion of encephalitogenic T-cell specificities. To determine if Treg cells constitute the major non-redundant protective pathway for E2, we evaluated E2 protection of EAE after targeted deletion of Foxp3 expression in Foxp3-DTR mice. Unexpectedly, E2-treated Foxp3-deficient mice were completely protected against clinical and histological myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide-induced EAE before succumbing to diphtheria toxin-induced mortality. This finding indicated the presence of alternative E2-dependent EAE-protective pathways that could compensate for the lack of Treg cells. Further investigation revealed that E2 treatment inhibited proliferation and expression of CCL2 and CXCL2, but enhanced secretion of interleukin-10 (IL-10) and IL-13 by MOG-35-55-specific spleen cells. These changes occurred concomitantly with increased expression of several chemokines and receptors, including CXCL13 and CXCR5, and the negative co-activation molecules, PD-L1 and B7.2, by B cells and dendritic cells. Furthermore, E2 treatment resulted in higher percentages of spleen and lymph node T cells expressing IL-17, interferon-γ and tumour necrosis factor-α, but with lower expression of CCR6, suggesting sequestration of MOG-35-55 peptide-specific T cells in peripheral immune organs. Taken together, these data suggest that E2-induced mechanisms that provide protection against EAE in the absence of Foxp3+ Treg cells include induction of regulatory B cells and peripheral sequestration of encephalitogenic T cells.
KW - B cells
KW - Experimental autoimmune encephalomyelitis
KW - Foxp3
KW - Foxp3-DTR
KW - Oestrogen
UR - http://www.scopus.com/inward/record.url?scp=79251602666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79251602666&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2567.2010.03380.x
DO - 10.1111/j.1365-2567.2010.03380.x
M3 - Article
C2 - 21091909
AN - SCOPUS:79251602666
SN - 0019-2805
VL - 132
SP - 340
EP - 347
JO - Immunology
JF - Immunology
IS - 3
ER -